WASHINGTON, Oct. 13 /PRNewswire-USNewswire/ -- Pharmaceutical Research and Manufacturers of America (PhRMA) President & CEO Billy Tauzin released the following statement about the Senate Finance Committee's vote on Chairman Baucus' health care reform proposal:
"Today's vote represents an important step forward for the millions of Americans who don't have access to high-quality and affordable health care coverage and services. Chairman Baucus has tirelessly shepherded one of the most important pieces of legislation in our lifetime and deserves a lot of credit for reaching out to members on both sides of the aisle.
"We recognize that a lot of work remains in both chambers, but we're still convinced that the Senate Finance Committee's bipartisan bill is the best blueprint for comprehensive health care reform, and we are going to do our part to try and get a bill on the President's desk this year."
The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country's leading pharmaceutical research and biotechnology companies, which are devoted to inventing medicines that allow patients to live longer, healthier, and more productive lives. PhRMA companies are leading the way in the search for new cures. PhRMA members alone invested an estimated $50.3 billion in 2008 in discovering and developing new medicines. Industry-wide research and investment reached a record $65.2 billion in 2008.
PhRMA Internet Address: http://www.phrma.org
For information on stories of hope and survival, visit: http://sharingmiracles.com/
For information on how innovative medicines save lives, visit: http://www.innovation.org
For information on the Partnership for Prescription Assistance, visit: http://www.pparx.org
For information on the danger of imported drugs, visit: http://www.buysafedrugs.info
For more information on public health emergencies, visit http://www.rxresponse.org
SOURCE Pharmaceutical Research and Manufacturers of America
|SOURCE Pharmaceutical Research and Manufacturers of America|
Copyright©2009 PR Newswire.
All rights reserved